Skye Bioscience is a clinical-stage biotechnology company developing next-generation therapies targeting G-protein-coupled receptors to treat obesity, overweight, and metabolic disorders. The company's lead candidate is nimacimab, a peripherally restricted monoclonal antibody that inhibits cannabinoid receptor 1 (CB1), a key regulator of energy metabolism and weight. Skye is advancing nimacimab through clinical development both as a standalone therapy and in combination with other metabolic drugs; the company's strategy also includes developing additional GPCR-targeting molecules, pursuing strategic partnerships, and expanding its pipeline through acquisitions. Revenue is anticipated from future regulatory approval and commercialization of nimacimab for obesity and related metabolic indications.